ICU Medical (NASDAQ:ICUI) Reaches New 1-Year High – Still a Buy?

ICU Medical, Inc. (NASDAQ:ICUI) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $167.00 and last traded at $157.1960, with a volume of 893 shares trading hands. The stock had previously closed at $157.60.

Wall Street Analysts Forecast Growth

A number of analysts have commented on ICUI shares. KeyCorp decreased their price target on shares of ICU Medical from $180.00 to $164.00 and set an “overweight” rating for the company in a research note on Monday, April 27th. Jefferies Financial Group upgraded shares of ICU Medical to a “strong-buy” rating in a report on Thursday, May 7th. Zacks Research raised shares of ICU Medical from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 29th. Needham & Company LLC raised ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a report on Wednesday, May 27th. Finally, Piper Sandler decreased their price objective on ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Three analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, ICU Medical currently has an average rating of “Buy” and an average target price of $168.40.

ICU Medical Trading Down 2.4%

The stock has a market capitalization of $3.84 billion, a PE ratio of 83.08, a price-to-earnings-growth ratio of 2.16 and a beta of 0.76. The company has a current ratio of 2.34, a quick ratio of 1.17 and a debt-to-equity ratio of 0.60. The firm has a 50-day moving average price of $137.86 and a 200-day moving average price of $138.91.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share for the quarter, beating the consensus estimate of $1.78 by $0.19. The company had revenue of $525.77 million during the quarter, compared to analyst estimates of $520.65 million. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The firm’s revenue for the quarter was down 12.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.72 earnings per share. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. As a group, equities analysts forecast that ICU Medical, Inc. will post 6.51 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director David C. Greenberg sold 2,424 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total value of $297,933.84. Following the transaction, the director owned 7,960 shares in the company, valued at approximately $978,363.60. This represents a 23.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the company’s stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total value of $303,623.76. Following the completion of the transaction, the vice president owned 19,460 shares in the company, valued at approximately $2,414,596.80. The trade was a 11.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in ICU Medical by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 2,714,746 shares of the medical instruments supplier’s stock worth $387,313,000 after acquiring an additional 89,755 shares during the last quarter. Janus Henderson Group PLC boosted its position in ICU Medical by 3.9% during the first quarter. Janus Henderson Group PLC now owns 2,676,012 shares of the medical instruments supplier’s stock worth $345,607,000 after purchasing an additional 99,256 shares during the period. Millennium Management LLC increased its stake in shares of ICU Medical by 173.4% in the third quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock worth $130,638,000 after purchasing an additional 690,694 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of ICU Medical by 6.8% in the first quarter. Dimensional Fund Advisors LP now owns 983,802 shares of the medical instruments supplier’s stock worth $127,053,000 after purchasing an additional 63,026 shares in the last quarter. Finally, State Street Corp raised its position in shares of ICU Medical by 2.8% in the fourth quarter. State Street Corp now owns 942,670 shares of the medical instruments supplier’s stock valued at $134,491,000 after purchasing an additional 25,545 shares during the period. Institutional investors own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.